HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $10

Benzinga · 08/29/2025 12:38
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $5 to $10.